Verona Pharma PLC
VRNA95.110USD
-2.110-2.17%
終値 06/25, 16:00（ET）15分遅れの株価
64.78B時価総額
損失額直近12ヶ月PER
詳細情報 Verona Pharma PLC 企業名
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
企業情報
企業コードVRNA
会社名Verona Pharma PLC
上場日Mar 30, 2005
設立日2005
最高経営責任者「CEO」Dr. David S. Zaccardelli
従業員数209
証券種類Depository Receipt
決算期末Mar 30
本社所在地Riverside
都市LONDON
証券取引所NASDAQ Global Market Consolidated
国United Kingdom
郵便番号SE1 2RE
電話番号442032834200
ウェブサイトhttps://www.veronapharma.com/
企業コードVRNA
上場日Mar 30, 2005
設立日2005
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
391.27K
-50.55%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Andrew Fisher ,
Andrew Fisher ,
General Counsel
General Counsel
--
--
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli
Dr. David S. Zaccardelli
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
391.27K
-50.55%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Andrew Fisher ,
Andrew Fisher ,
General Counsel
General Counsel
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Sun, May 18
更新時刻: Sun, May 18
株主統計
種類
株主統計
株主統計
比率
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
株主統計
株主統計
比率
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
種類
株主統計
比率
Investment Advisor/Hedge Fund
25.31%
Hedge Fund
23.50%
Investment Advisor
16.08%
Private Equity
12.03%
Individual Investor
10.40%
Venture Capital
5.02%
Research Firm
3.63%
Family Office
1.18%
Bank and Trust
0.26%
Other
2.58%
機関投資家保有株
更新時刻: Tue, Mar 4
更新時刻: Tue, Mar 4
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q1
362
99.25M
116.64%
+16.32M
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
2022Q4
162
65.88M
87.36%
-542.66K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Perceptive Advisors LLC
6.39M
7.52%
+76.17K
+1.21%
Dec 31, 2024
Janus Henderson Investors
1.67M
1.96%
+624.37K
+59.87%
Dec 31, 2024
Frazier Life Sciences Management, L.P.
3.38M
3.98%
--
--
Dec 31, 2024
Ali (Behbahani)
3.19M
3.76%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
3.13M
3.69%
+706.28K
+29.11%
Dec 31, 2024
RTW Investments L.P.
1.82M
2.14%
+1.82M
--
Dec 31, 2024
New Enterprise Associates (NEA)
4.08M
4.81%
-1.50M
-26.86%
Jan 16, 2025
Summit Partners Public Asset Management, LLC
1.90M
2.24%
+1.90M
--
Dec 31, 2024
Wellington Management Company, LLP
3.03M
3.56%
+1.15M
+61.03%
Dec 31, 2024
詳細を見る
関連ETF
更新時刻: Fri, Jun 6
更新時刻: Fri, Jun 6
銘柄名
比率
ALPS Medical Breakthroughs ETF
5.66%
AdvisorShares Dorsey Wright ADR ETF
5.49%
First Trust IPOX Europe Equity Opportunities ETF
1.67%
First Trust International Equity Opportunities ETF
0.85%
Invesco Nasdaq Biotechnology ETF
0.67%
ProShares Ultra Nasdaq Biotechnology
0.63%
iShares Biotechnology ETF
0.39%
JPMorgan Healthcare Leaders ETF
0.39%
Even Herd Long Short ETF
0.36%
Goldman Sachs Innovate Equity ETF
0.14%
詳細を見る
ALPS Medical Breakthroughs ETF
比率5.66%
AdvisorShares Dorsey Wright ADR ETF
比率5.49%
First Trust IPOX Europe Equity Opportunities ETF
比率1.67%
First Trust International Equity Opportunities ETF
比率0.85%
Invesco Nasdaq Biotechnology ETF
比率0.67%
ProShares Ultra Nasdaq Biotechnology
比率0.63%
iShares Biotechnology ETF
比率0.39%
JPMorgan Healthcare Leaders ETF
比率0.39%
Even Herd Long Short ETF
比率0.36%
Goldman Sachs Innovate Equity ETF
比率0.14%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
